American scientists have developed an innovative vaccine that is 88% effective against several aggressive cancers, including melanoma, pancreatic cancer and breast cancer.

A major breakthrough in cancer research. An experimental "super vaccine" against several aggressive cancers has been developed by researchers at the University of Massachusetts Amherst (USA).

Although the tests have only been conducted on mice so far, the results published in the journal Cell Reports Medicine are very promising for millions of patients worldwide.

The scientific team combined cancer-specific antigens, which allow the immune system to recognize the tumor, with adjuvants that strongly stimulate the immune defenses, in nanoparticles.

“By designing these nanoparticles to activate the immune system via multi-pathway activation that combines with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates,” said Prabhani Atukorale, assistant professor of biomedical engineering and co-author of the study.

88% OF RODENTS IN GOOD HEALTH

Unlike traditional vaccines, which stimulate only one immune system, this vaccine works on multiple fronts simultaneously. “This dual-adjuvant vaccine stimulates both the innate and adaptive immune systems, enabling a targeted response and lasting immune memory ,” the researcher added.

The mice received three injections against melanoma, the rarest and most serious form of skin cancer, pancreatic cancer and triple-negative breast cancer, which is particularly aggressive.

Ultimately, 88% of the rodents exposed to pancreatic cancer, 75% to breast cancer, and 69% to melanoma remained healthy. None of them developed metastases, meaning cancers spread to other organs such as the lungs . "Metastases are the main obstacle to cancer," the scientist emphasized.

Although the results are still experimental, experts are optimistic. "This suggests a future where personalized cancer vaccines could work alongside existing treatments to help prevent cancer recurrence," said Aliasger K. Salem, PhD, co-author of the research.